CSPI Urges FDA To Follow “Intent” Of AER Law In Labeling Guidance
This article was originally published in The Tan Sheet
Executive Summary
The Center for Science in the Public Interest is urging FDA to require a statement on labels for OTC drugs and dietary supplements advising consumers to make any reports of any adverse reactions using telephone numbers or mailing addresses also printed on the packages